Abstract
To the Editor: Risankizumab is a humanized IgG1 monoclonal antibody that binds to the p19 subunit of interleukin 23 with remarkable safety and efficacy for treatment of moderate-to-severe plaque psoriasis in phase 3 randomized controlled trials (RCTs).1-3 Data on how findings from RCTs translate to real-world experience are limited.4 To better understand the safety and efficacy of risankizumab at 16 weeks in clinical practice, a retrospective chart review was conducted at 5 academic centers and 2 community practices in Canada.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
